Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
1,355
datasets available to search
ShareScore release 0.7.1
Dataset results
1,355 results for “Autoimmunity”
Study to Assess the Safety, Tolerability, Efficacy and PK of APL-2 in Patients With Warm Type Autoimmune Hemolytic Anemia (wAIHA) or Cold Agglutinin Disease (CAD)
ClinicalTrials.gov study NCT03226678. IPD Sharing: NO. Countries: 1. Publications: 1.
Evaluating the Effectiveness of Intravenous Immunoglobulin Therapy in Autoimmune Autonomic Ganglionopathy
ClinicalTrials.gov study NCT01522235. IPD Sharing: YES. Countries: 1. Publications: 29.
Normalized linear counts from NanoString autoimmune profiling panel and summary of statistical analyses
Open the record for dataset details and reuse information.
Transcobalamin receptor antibodies in autoimmune vitamin B12 central deficiency
Open the record for dataset details and reuse information.
AutoCore: network-based definition of the core module of human autoimmunity and autoinflammation
Open the record for dataset details and reuse information.
Autoimmunity-associated allele of tyrosine phosphatase gene PTPN22 enhances anti-viral immunity
Open the record for dataset details and reuse information.
Autoantibody discovery across monogenic, acquired, and COVID19-associated autoimmunity with scalable PhIP-Seq
Open the record for dataset details and reuse information.
The extrafollicular response is sufficient to drive initiation of autoimmunity and early disease hallmarks of lupus
Open the record for dataset details and reuse information.
Data from: Autoimmune encephalitis: a costly condition
Objective: To assess the inpatient hospitalization burden and costs of patients with autoimmune encephalitis (AE) at a tertiary care institution. Methods: Adult inpatients with AE were identified retrospectively from July 1, 2005 – June 30, 2015. Demographic and clinical data were collected and analyzed. Billing data were compared to that of patients with herpes simplex encephalitis (HSE). Charges were adjusted for inflation. Results: Of 244 admissions for encephalitis reviewed, 63 patients met criteria for probable or definite AE. Thirty-one (49%) patients were antibody-positive, and twenty-seven (43%) were admitted to the intensive care unit (ICU). Median hospital charges per AE patient were over $70k, median length of stay (LOS) was 15 days, and in hospital mortality was 6%. ICU patients had substantially higher median hospital charges (ICU $173k/ admission vs. non-ICU $50k/ admission, p<0.001). LOS was strongly associated with charges and was driven by delay in diagnosis of AE, prolonged treatment courses, and lack of response to therapy. In comparison with HSE, median hospital charges per AE patient were nearly 4 times higher, median AE LOS was 3 times higher, and total charges over the study period were nearly twice as high. Conclusions: AE patients utilized more inpatient healthcare resources per patient during a ten-year period than HSE at our institution. ICU-admitted AE patients were responsible for a substantially higher financial burden than non-ICU-admitted AE patients. Our data underscore the need for the development of novel diagnostic and therapeutic modalities to improve patient outcomes and decrease hospital burden in AE.
Gene Signature predicts autoimmune toxicity in metastatic melanoma
Open the record for dataset details and reuse information.
Immune signatures predict development of autoimmune toxicity in immune checkpoint inhibitor-treated patients with cancer
<p><strong>Immune signatures predict development of autoimmune toxicity in immune</strong><strong> checkpoint inhibitor-treated patients with cancer</strong></p> <p> </p> <p>Nicolas Gonzalo Nuñez<sup>1</sup>*, Fiamma Berner<sup>2</sup>*, Ekaterina Friebel<sup>1</sup>*, Susanne Unger<sup>1</sup>, Nina Wyss<sup>2,3</sup>, Julia Martinez Gomez<sup>4</sup>, Mette-Triin Purde<sup>2</sup>, Rebekka Niederer<sup>2,3</sup>, Maximilian Porsch<sup>5</sup>, Christa Lichtensteiger<sup>2</sup>, Rafaela Kramer<sup>6</sup>, Michael Erdmann<sup>6</sup>, Christina Schmitt<sup>7</sup>, Lucy Heinzerling<sup>6,7</sup>, Marie-Therese Abdou<sup>2</sup>, Julia Karbach<sup>8</sup>, Dirk Schadendorf<sup>9</sup>, Lisa Zimmer<sup>9</sup>, Selma Ugurel<sup>9</sup>, Niklas Klümper<sup>10,11,12</sup>, Michael Hölzel<sup>10,11</sup>, Laura Power<sup>1</sup>, Stefanie Kreutmair<sup>1</sup>, Mariaelena Capone<sup>13</sup>, Gabriele Madonna<sup>13</sup>, Lacin Cevhertas<sup>14,15</sup>, Anja Heider<sup>14</sup>, Teresa Amaral<sup>16,17</sup>, Omar Hasan Ali<sup>2,3,4,18</sup>, David Bomze<sup>2,19</sup>, Florentia Dimitriou<sup>4</sup>, Stefan Diem<sup>20</sup>, Paolo Antonio Ascierto<sup>13</sup>, Reinhard Dummer<sup>4</sup>, Elke Jäger<sup>8</sup>, Christoph Driessen<sup>20</sup>, Mitchell P. Levesque<sup>4</sup>, Willem van de Veen<sup>14</sup>, Markus Joerger<sup>20</sup>, Martin Früh<sup>20,21</sup>, Burkhard Becher<sup>1</sup>**, Lukas Flatz<sup>2,3,4,20,22</sup>**</p> <p> </p> <p>*/** these authors contributed equally</p> <p> Affiliations</p> <p>1. Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland</p> <p>2. Institute of Immunobiology, Medical Research Center, Kantonsspital St. Gallen, St.Gallen, Switzerland</p> <p>3. Department of Dermatology, Kantonsspital St. Gallen, St.Gallen, Switzerland</p> <p>4. Department of Dermatology, University Hospital Zurich, Zurich, Switzerland</p> <p>5. Department of Radiology, Kantonsspital St. Gallen, St.Gallen, Switzerland</p> <p>6. Department of Dermatology, University of Erlangen-Nuremberg, Erlangen, Germany</p> <p>7. Ludwig Maximilian University of Munich, Munich, Germany</p> <p>8. Department of Oncology and Hematology, Krankenhaus Nordwest, Frankfurt, Germany</p> <p>9. Department of Dermatology, Comprehensive Cancer Center (Westdeutsches Tumorzentrum) University Hospital Essen, Essen, Germany</p> <p>10. Institute for Experimental Oncology, University Hospital Bonn, Bonn, Germany</p> <p>11. Center for Integrated Oncology Cologne/Bonn, University Hospital Bonn, Bonn, Germany</p> <p>12. Department of Urology, University Hospital Bonn, Bonn, Germany</p> <p>13. Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale, Napoli, Italy</p> <p>14. Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland</p> <p>15. Department of Medical Immunology, Institute of Health Sciences, Bursa Uludag University, Bursa, Turkey</p> <p>16. Skin Cancer Center, Department of Dermatology, University Hospital Tübingen, Tübingen, Germany</p> <p>17. iFIT Cluster of Excellence (EXC 2180), University of Tübingen, Tübingen, Germany</p> <p>18. Department of Medical Genetics, Life Sciences Institute, University of British Columbia, Vancouver, Canada</p> <p>19. Sackler Faculty of Medicine, Tel-Aviv University, Israel</p> <p>20. Department of Oncology, Kantonsspital St. Gallen, St.Gallen, Switzerland</p> <p>21. Department of Medical Oncology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland</p> <p>22. Universitäts-Hautklinik, University of Tübingen, Tübingen, Germany</p> <p> </p> <p> </p>
Public GWAS results for metabolic, blood cell, and autoimmune traits
<p>These data can be used to replicate the analysis in Morrison et al (2024) "Genetic Factor Analysis for Characterizing Phenome-Wide Patterns of Genetic Pleiotropy". <a href="https://github.com/jean997/gfa_manuscript/">Please see our github repository for more details.</a> </p>
Sex-Based Differences in Thyroid Plasma B Cell Infiltration: Implications for Autoimmune Disease Susceptibility - Table S1
<p>This is the supplementary table for the manuscript entitled "Sex-Based Differences in Thyroid Plasma B Cell Infiltration: Implications for Autoimmune Disease Susceptibility"</p>
Data from: Lupus and inflammatory bowel disease share a common set of microbiome features distinct from other autoimmune disorders
<p>Supplemental data for "Lupus and inflammatory bowel disease share a common set of microbiome features distinct from other autoimmune disorders"</p>
Dataset related to article "Dose-Dependent Impairment of the Immune Response to the Moderna-1273 mRNA Vaccine by Mycophenolate Mofetil in Patients with Rheumatic and Autoimmune Liver Diseases"
<p>This record contains data related to article “Dose-Dependent Impairment of the Immune Response to the Moderna-1273 mRNA Vaccine by Mycophenolate Mofetil in Patients with Rheumatic and Autoimmune Liver Diseases”</p> <p>The purpose of this study was to evaluate the efficacy and safety of the Moderna-1273 mRNA vaccine for SARS-CoV-2 in patients with immune-mediated diseases under different treatments. Anti-trimeric spike protein antibodies were tested in 287 patients with rheumatic or autoimmune diseases (10% receiving mycophenolate mofetil, 15% low-dose glucocorticoids, 21% methotrexate, and 58% biologic/targeted synthetic drugs) at baseline and in 219 (76%) 4 weeks after the second Moderna-1273 mRNA vaccine dose. Family members or caretakers were enrolled as the controls. The neutralizing serum activity against SARS-CoV-2-G614, alpha, and beta variants in vitro and the cytotoxic T cell response to SARS-CoV-2 peptides were determined in a subgroup of patients and controls. Anti-SARS-CoV-2 antibody development, i.e., seroconversion, was observed in 69% of the mycophenolate-treated patients compared to 100% of both the patients taking other treatments and the controls (<em>p</em> &lt; 0.0001). A dose-dependent impairment of the humoral response was observed in the mycophenolate-treated patients. A daily dose of &gt;1 g at vaccination was a significant risk factor for non-seroconversion (ROC AUC 0.89, 95% CI 0.80-98, <em>p</em> &lt; 0.0001). Moreover, in the seroconverted patients, a daily dose of &gt;1 g of mycophenolate was associated with significantly lower anti-SARS-CoV-2 antibody titers, showing slightly reduced neutralizing serum activity but a comparable cytotoxic response compared to other immunosuppressants. In non-seroconverted patients treated with mycophenolate at a daily dose of &gt;1 g, the cytotoxic activity elicited by viral peptides was also impaired. Mycophenolate treatment affects the Moderna-1273 mRNA vaccine immunogenicity in a dose-dependent manner, independent of rheumatological disease.</p> <p>.</p>
NanoString autoimmune profiling panel normalized linear counts and summary of statistical analyses
<p>Occupational exposure to respirable crystalline silica (cSiO<sub>2</sub>) is linked to the development of lupus. Preclinical studies have revealed weekly repeated intranasal exposure to 1 mg cSiO<sub>2</sub> in young (8-11 wk-old) female NZBWF1 lupus-prone mice, a life-stage equivalent to 12–20-yr-old humans, triggers autoimmunity in the lungs and kidneys that is prevented by dietary supplementation with the omega-3 fatty acid docosahexaenoic acid (DHA).</p> <p><strong>Methods</strong>: Here, we characterized cSiO<sub>2</sub>'s and DHA's effects in mature adult (16–19-wk-old) female NZBWF1 mice, an age period that coincides with the onset of immunological tolerance breach and that is more representative of the age (>20-yr-old) of cSiO<sub>2</sub>-exposed workers. We fed mice either a control diet (CON) or diet amended with DHA calorically equivalent to a human daily dose of 5 g. After 2 wk, we intranasally instilled them with either saline vehicle (VEH) or 1 mg of cSiO<sub>2</sub> weekly for 4 wk. Cohorts were terminated 1 and 5 wk after the final installation. Lungs were then analyzed for inflammatory cell counts, chemokines, histopathology, B-and T-cell infiltration, autoantibody profile, and inflammatory/autoimmune gene signatures and results further related to autoimmune glomerulonephritis onset.</p> <p><strong>Results</strong>: VEH/CON mice displayed no lung or kidney pathology at either time point. In contrast, cSiO<sub>2</sub>/CON mice exhibited mild ectopic lymphoid tissue (ELT) formation in the lungs at 1 wk, which increased significantly by 5 wk. Lungs from cSiO<sub>2</sub>/CON mice also showed elevations in BALF cellularity, chemokine production, CD3 + T-cells, CD45R + B-cells, IgG + plasma cells, inflammatory/autoimmune gene expression, IgG autoantibodies. cSiO<sub>2</sub>/CON mice had visible glomerular hypertrophy and IgG deposition. Dietary DHA supplementation suppressed all these endpoints.</p> <p><strong>Discussion</strong>: Consistent with young mice, intranasal cSiO<sub>2</sub> exposure in mature adult NZBWF1 lupusprone mice elicited early pulmonary inflammation that served as a nexus for autoimmunity, suggesting these life-stage differences are not critical for cSiO2-triggered autoimmune response in this preclinical model. DHA supplementation at a translationally relevant human dosage effectively mitigated cSiO<sub>2</sub>-induced inflammation/autoimmunity in mature adult mice, resembling the protective effects observed in young mice. Together these findings further highlight the therapeutic potential of omega-3 fatty acids in mitigating toxicant-triggered autoimmune responses.</p>
Autoimmune Intervention Mastery Course Study
ClinicalTrials.gov study NCT05057676. IPD Sharing: NO. Countries: 1. Publications: 10.
Safety Study of CC312 in Autoimmune Disease Patients
ClinicalTrials.gov study NCT06888960. IPD Sharing: UNDECIDED. Countries: 1. Publications: 3.
Genetic and Environmental Risk Factors of Type 1 Autoimmune Diabetes and Its Early Complications
ClinicalTrials.gov study NCT02212522. IPD Sharing: NO. Countries: 1. Publications: 1.
Combination Chemotherapy and Rituximab in Treating Patients With Chronic Lymphocytic Leukemia (CLL) That Did Not Respond to Fludarabine, CLL With Autoimmune Haemolytic Anemia (AIHA) or Richter's Trans
ClinicalTrials.gov study NCT00309881. IPD Sharing: UNDECIDED. Countries: 1. Publications: 1.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.